Differential Expression of Polyamine Pathways in Human Pancreatic Tumor Progression and Effects of Polyamine Blockade on Tumor Microenvironment.
CD86
DFMO
immune suppression
macrophage
pancreatic ductal adenocarcinoma
polyamine blockade therapy
polyamine metabolism
polyamine transport inhibitor
survival
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Dec 2021
20 Dec 2021
Historique:
received:
09
11
2021
revised:
12
12
2021
accepted:
14
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Pancreatic cancer is the fourth leading cause of cancer death. Existing therapies only moderately improve pancreatic ductal adenocarcinoma (PDAC) patient prognosis. The present study investigates the importance of the polyamine metabolism in the pancreatic tumor microenvironment. Relative mRNA expression analysis identified differential expression of polyamine biosynthesis, homeostasis, and transport mediators in both pancreatic epithelial and stromal cells from low-grade pancreatic intraepithelial neoplasia (PanIN-1) or primary PDAC patient samples. We found dysregulated mRNA levels that encode for proteins associated with the polyamine pathway of PDAC tumors compared to early lesions. Next, bioinformatic databases were used to assess expression of select genes involved in polyamine metabolism and their impact on patient survival. Higher expression of pro-polyamine genes was associated with poor patient prognosis, supporting the use of a polyamine blockade therapy (PBT) strategy for inhibiting pancreatic tumor progression. Moreover, PBT treatment of syngeneic mice injected intra-pancreatic with PAN 02 tumor cells resulted in increased survival and decreased tumor weights of PDAC-bearing mice. Histological assessment of PBT-treated tumors revealed macrophage presence and significantly increased expression of CD86, a T cell co-stimulatory marker. Collectively, therapies which target polyamine metabolism can be used to disrupt tumor progression, modulate tumor microenvironment, and extend overall survival.
Identifiants
pubmed: 34945011
pii: cancers13246391
doi: 10.3390/cancers13246391
pmc: PMC8699198
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Florida Department of Health Bankhead-Coley Cancer Research Program
ID : 8BC05
Références
Immunity. 2016 May 17;44(5):973-88
pubmed: 27192564
Nat Metab. 2019 Jan;1(1):47-57
pubmed: 31131364
J Biol Chem. 2010 Oct 8;285(41):31885-94
pubmed: 20685649
Immunity. 2017 Aug 15;47(2):323-338.e6
pubmed: 28813661
Mol Biol Cell. 2013 May;24(10):1529-43
pubmed: 23515223
Biosci Rep. 2014 Nov 21;34(6):e00153
pubmed: 25301005
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640192
J Exp Clin Cancer Res. 2011 Oct 11;30:95
pubmed: 21988863
Clin Cancer Res. 1999 May;5(5):945-51
pubmed: 10353725
Oncotarget. 2019 Oct 01;10(55):5713-5723
pubmed: 31620246
Protein Sci. 2008 May;17(5):793-802
pubmed: 18369191
Cancer Prev Res (Phila). 2014 Dec;7(12):1198-209
pubmed: 25248858
Trends Cancer. 2018 Jun;4(6):418-428
pubmed: 29860986
J Hematol Oncol. 2017 Mar 28;10(1):76
pubmed: 28351381
Med Sci (Basel). 2018 May 25;6(2):
pubmed: 29799508
Oncotarget. 2018 Apr 10;9(27):19396-19405
pubmed: 29721211
Biology (Basel). 2017 Mar 07;6(1):
pubmed: 28272331
Exp Cell Res. 2008 Feb 15;314(4):707-19
pubmed: 18201699
Am J Cancer Res. 2016 Jun 01;6(6):1231-52
pubmed: 27429841
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Front Cell Dev Biol. 2021 Jan 11;8:607209
pubmed: 33505964
Oncoimmunology. 2014 Jan 1;3(1):e27360
pubmed: 24711956
Nat Rev Drug Discov. 2007 May;6(5):373-90
pubmed: 17464296
Nature. 1992 Apr 16;356(6370):607-9
pubmed: 1313950
Mol Cancer Ther. 2020 Oct;19(10):2012-2022
pubmed: 32747421
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
J Biol Chem. 2006 May 26;281(21):14529-32
pubmed: 16459331
Cancer Immunol Res. 2014 Mar;2(3):274-85
pubmed: 24778323
Mol Pharm. 2018 Feb 5;15(2):369-376
pubmed: 29299930
Clin Cancer Res. 2009 Feb 1;15(3):758-61
pubmed: 19188144
J Med Chem. 2014 Jan 23;57(2):348-63
pubmed: 24405276
Nature. 2011 Sep 07;477(7365):490-4
pubmed: 21900894
Amino Acids. 2014 Mar;46(3):595-603
pubmed: 23836422
Sci Transl Med. 2019 Jan 30;11(477):
pubmed: 30700572
J Biol Chem. 2021 Jan-Jun;296:100182
pubmed: 33310703
Amino Acids. 2014 Mar;46(3):655-60
pubmed: 23851697
Cancer Cell. 2020 Dec 14;38(6):788-802
pubmed: 32946773
J Biol Chem. 2008 Feb 15;283(7):4241-51
pubmed: 18089555
Oncotarget. 2017 Aug 24;8(48):84140-84152
pubmed: 29137411
Biochem J. 2016 Oct 1;473(19):2937-53
pubmed: 27679855
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
J Biol Chem. 2003 Nov 21;278(47):47181-9
pubmed: 12972423
Biochem J. 2004 Jan 1;377(Pt 1):257-64
pubmed: 14519103
Int J Cancer. 2018 May 15;142(10):1968-1976
pubmed: 29134652
J Cell Physiol. 2009 Sep;220(3):680-9
pubmed: 19472210
J Biol Chem. 2005 Dec 30;280(52):42801-8
pubmed: 16263714